SEC EDGAR · company profile · free

Merck & Co., Inc. due diligence

Who Merck & Co., Inc. (MRK) is on the public record: identity, annual results, what it filed in the last year and why, straight from SEC EDGAR.

1000 filings in EDGAR's recent index, 644 of them Form 4 insider filings · view the filings on SEC EDGAR · source: SEC EDGAR submissions index and XBRL financial data

At a glance

Merck & Co., Inc. (MRK) is a large accelerated filer incorporated in New Jersey, classified under SIC 2834 (Pharmaceutical Preparations), and lists on NYSE. Its fiscal year ends December 31. It has also filed as Merck & Co. Inc. and SCHERING PLOUGH CORP.

For the fiscal year ended December 31, 2025, its 10-K reported revenue of $65.0B, up 1.3% from the year before, net income of $18.3B, and total assets of $137B.

In the twelve months to October 9, 2026 it made 145 filings on EDGAR, including 1 annual report, 3 quarterly reports, 7 current reports on Form 8-K, and 81 Form 4 insider filings, plus 6 prospectus supplements and free writing prospectuses for its securities offerings. Its 8-Ks were filed most often for results of operations (4), other events (2), and shareholder vote results (1).

CIK
0000310158
Filer status
Large accelerated filer
Industry (SIC)
Pharmaceutical Preparations (2834)
Incorporated
New Jersey
Listed on
NYSE
Tickers
MRK
Fiscal year end
12-31

Annual results

Fiscal year endedRevenueNet incomeTotal assets
2025-12-31$65.0B +1.3%$18.3B +6.6%$137B
2024-12-31$64.2B +6.7%$17.1B +4589.6%$117B
2023-12-31$60.1B$365M$107B
As reported in each 10-K's XBRL data on SEC EDGAR (revenue tag Revenues); a later 10-K's restatement replaces the earlier figure.
FilingFiledPeriodAccession
Annual report (10-K)2026-02-242025-12-310000310158-26-000063
Quarterly report (10-Q)2026-08-072026-06-300000310158-26-000212
Current report (8-K)2026-08-042026-08-040001104659-26-090045

Filing activity

145 filings since 2025-10-09, 6 of them prospectus supplements and free writing prospectuses (not listed below). By form:

4
81
144
22
8-K
7
SC TO-T/A
5
13F-HR
4
10-Q
3
11-K
3
3
3

8-K items in the last 12 months: results of operations (Item 2.02, 4) · other events (Item 8.01, 2) · shareholder vote results (Item 5.07, 1).

FiledFormDocumentPeriod
2026-10-014PRIMARY DOCUMENT2026-09-30
2026-10-014PRIMARY DOCUMENT2026-09-30
2026-10-014PRIMARY DOCUMENT2026-09-30
2026-09-013PRIMARY DOCUMENT2026-09-01
2026-08-134PRIMARY DOCUMENT2026-08-13
2026-08-13144Form 144 notice of proposed sale
2026-08-134PRIMARY DOCUMENT2026-08-12
2026-08-12144Form 144 notice of proposed sale
2026-08-12144Form 144 notice of proposed sale
2026-08-124PRIMARY DOCUMENT2026-08-10
free alert

Free. One email a day at most, only when something changes. Confirm by email first; unsubscribe with one click. Privacy.

The full due-diligence dossier on Merck & Co., Inc.

The free view above is identity and filing dates. The paid dossier reads the filings: business and segments, financial trend, insider and institutional activity, litigation and risk-factor themes, recent news, and the red flags, every claim cited and delivered with a data appendix.

agents: POST /v1/dossier with {"ticker":"MRK"} over x402 or MPP, $0.85

Sample output and API docs · all reports

MRK insider filingsAll company profiles13F fund holdingsAll reports

Generated from public SEC EDGAR filings. Filing data is shown as filed. This is information, not investment advice.